@article{Pompilio_Morabito_Cortinovis_Integlia_2022, title={Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations}, volume={9}, url={https://journals.aboutscience.eu/index.php/grhta/article/view/2351}, DOI={10.33393/grhta.2022.2351}, abstractNote={<p class="abstract"><strong>Background:</strong> The current clinical practice for patients affected by Non-Small Cell Lung Cancer (NSCLC) with uncommon mutation is based on afatinib and osimertinib, second and third generation of Tyrosine Kinase Inhibitor (TKI) respectively. For uncommon EGFR mutations, it is still unclear which EGFR TKI is most effective, since there are few dedicated prospective studies and Next Generation Sequencing (NGS) techniques trace an increasingly large and sometimes little-known population of EGFR mutations.</p> <p class="abstract"><strong>Objective:</strong> To determine the economic impact associated to afatinib and osimertinib, a Budget Impact model considering a 3-year time horizon with two scenarios was developed: a first scenario, called AS IS, based on treatment with afatinib and osimertinib according to a distribution of market shares as emerged from clinical practice; a second suitable scenario, called TO BE, based on reviewed literature data, assuming for each year a 10%, 15% and 20% increase in afatinib use, respectively.</p> <p class="abstract"><strong>Methods:</strong> Budget Impact analysis was conducted using a dynamic cohort model, in which the annual number of patients with NSCLC and uncommon mutations was equally distributed over 12 months. Progression-free survival (PFS) data for afatinib and osimertinib were extrapolated up to 36 months from published Kaplan Meier curves, and then the number of patients was estimated for each treatment.</p> <p class="abstract"><strong>Results:</strong> The increase of 10% in afatinib use allowed a saving of drug acquisition costs for the Italian NHS, over the 3-year time horizon, of –€ 622,432. The univariate sensitivity analysis shows the market share of osimertinib to be the parameter significantly affecting the results achieved in the base case.</p> <p class="abstract"><strong>Conclusions:</strong> The potential increase in the use of afatinib in patients with NSCLC and uncommon mutations leads to lower drug acquisition costs, lower Budget Impact and a saving of money for the Italian NHS.</p>}, number={1}, journal={Global and Regional Health Technology Assessment}, author={Pompilio, Giuseppe and Morabito, Alessandro and Cortinovis, Diego L. and Integlia, Davide}, year={2022}, month={Jan.}, pages={22–29} }